QUANTA™ DIALYSIS SYSTEM RECEIVES FDA CLEARANCE FOR HOME HEMODIALYSIS
29. October 2024
Aignostics Secures $34 Million Series B to Enhance Precision Medicine with AI
22. October 2024
Seamless Therapeutics to Present New Data at ESGCT Demonstrating its Ability to Reprogram Large Serine Recombinases to Specific Target Sites in the Human Genome
9. October 2024
Beckman Coulter and SphingoTec Partner to Improve Kidney Health Assessment in Critical Care
19. September 2024
ONWARD® Medical Announces Third Implant of BrainComputer Interface (BCI) System to Restore Movement after Spinal Cord Injury
10. September 2024
Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
10. September 2024
CorFlow Therapeutics AG completes €44 million Series B financing to support the advancement of a novel diagnostic and drug delivery platform for microvascular obstruction (MVO) in heart attack patients
9. July 2024
Wellington announces a new investment in SciRhom
2. July 2024
Carisma Therapeutics Announces Changes to its Board of Directors
25. June 2024
UroMems Raises Record $47 million (€44 Million) in Series C Financing to Fund Pivotal Clinical Trials of the UroActive™ System, the First Smart Automated Implant to Treat Stress Urinary Incontinence
25. June 2024
Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors
8. May 2024
Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024
10. April 2024
Analyst (f/m/d) @ Wellington Partners Life Sciences
10. April 2024
Investment Manager (f/m/d) @ Wellington Partners Life Sciences
8. April 2024
MMI Receives FDA Authorization to Commercialize Symani® Surgical System in the U.S.
5. April 2024
ONWARD® Medical Submits De Novo Application to FDA for its ARC-EX® System
1. April 2024
Carisma Therapeutics Announces Changes to its Board of Directors
26. March 2024
TRiCares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer
14. March 2024
Bayer and Aignostics to collaborate on next generation precision oncology
21. February 2024
MMI Raises $110 Million in Series C Financing
15. February 2024
UroMems Announces Results of First-Ever Smart Artificial Urinary Sphincter Implant in Female Patient to Treat Stress Urinary Incontinence
18. January 2024
eGenesis and OrganOx Announce Successful Use of a Genetically Engineered Porcine Liver with a Human Donor
14. December 2023
First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
13. December 2023
UroMems Reaches Significant Milestone: Successful Results in Clinical Feasibility Study of UroActive™ Smart Implant for Stress Urinary Incontinence Treatment
8. November 2023
Nature Medicine Publication Highlights Potential for ONWARD® ARC Therapy™ to Improve Mobility After Parkinson’s Disease
6. November 2023
Wellington Partners promotes Johannes Fischer and Varun Gupta to Partner
31. October 2023
Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC
25. October 2023
Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023
24. October 2023
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
11. October 2023
MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus
11. October 2023
Sidekick Health announces landmark acquisition, expanding its portfolio to offer regulated Prescription Digital Therapeutics
11. October 2023
eGenesis Announces Publication in Nature of Landmark Preclinical Data Demonstrating Long-Term Survival with Genetically Engineered Porcine Kidneys
25. September 2023
4SC: Landmark RESMAIN study data presented at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting
11. September 2023
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
30. August 2023
Confo Therapeutics Appoints Dieter Weinand, Former CEO of Bayer Pharmaceuticals, as Independent Chairman
23. August 2023
Quanta™ Announces Enrollment Completion in Home Run Study
10. August 2023
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
4. August 2023
Quanta™ Receives FDA 510(k) Clearance for Expanded Indication of Continuous Renal Replacement Therapies
31. July 2023
BioM-Podcast: "In der Frühphase, in der Forschung sind wir Weltmeister"
24. July 2023
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
29. June 2023
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors
22. June 2023
nyra health raises €4.5m Seed Round to advance its digital neuro-therapy
31. May 2023
Resminostat: 4SC Filed Letter of Intent to the European Medicines Agency (EMA)
4SC AG – RESMAIN Trial Meets Primary Endpoint in Cutaneous T-Cell Lymphoma (CTCL)
4. May 2023
Upon FDA approval, Advanced Medical Balloons launches innovative hygh-tec catheter system for ICU stool drainage in U.S. market
2. May 2023
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
21. April 2023
UroMems Granted Safer Technologies Program Designation from FDA for Smart Implant to Treat Stress Urinary Incontinence
17. April 2023
MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults
3. April 2023
Sidekick Health chosen as partner for White House’s CancerX project to rapidly accelerate the pace of cancer innovation in the U.S.
30. March 2023
Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases
23. March 2023
ImCheck Appoints Thomas Civik as Independent Chairman of the Board
16. March 2023
Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases
8. March 2023
Carisma Therapeutics Closes Merger with Sesen Bio
2. March 2023
Confo Therapeutics Announces Global Licensing Agreement With Lilly For Peripheral Pain Candidate, CFTX-1554
5. January 2023
MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine
16. December 2022
MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus
13. December 2022
TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation
9. December 2022
ONWARD Reports Interim Clinical Outcomes for Implantable ARC Therapy Demonstrating Potential to Improve Blood Pressure Regulation after Spinal Cord Injury
29. November 2022
UroMems Initiates First-in-Human Study of Its Smart Implant to Treat Stress Urinary Incontinence
17. November 2022
Boditech Med and SphingoTec close global licensing agreement for kidney function biomarker Proenkephalin A 119-159 (penKid)
13. October 2022
NEUWAY Pharma and WACKER Launch Research Project to Develop RNA-Based Actives for the Treatment of Central Nervous System Diseases
12. October 2022
Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME
10. October 2022
Immatics Announces $110 Million Underwritten Offering of Ordinary Shares
5. October 2022
ONWARD Announces Appointment of Vivian Riefberg to Board of Directors
21. September 2022
Sesen Bio and Carisma Therapeutics Announce Merger Agreement
19. September 2022
Aignostics Raises €14m Series A to Advance AI-powered Pathology
14. September 2022
ONWARD Reports Positive Topline Results from a Pivotal Study to Restore Arm and Hand Function in People with Spinal Cord Injury
12. July 2022
Quanta Dialysis Technologies: Team behind compact dialysis machine wins award for UK’s top engineering innovation of 2022
13. June 2022
ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
3. June 2022
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
19. May 2022
TRiCares Announces Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Canada
18. May 2022
Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors
12. May 2022
Koa Health Partners with Virgin Pulse to Extend Mental Health Programs via VP+ Program
11. May 2022
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors
10. May 2022
UroMems Appoints Steffen Hovard to Chairman of the Board of Directors
9. May 2022
Digital Therapeutics Leader Sidekick Raises $55M Series B To Drive Further Growth
25. April 2022
TRiCares Announces Successful First in Human Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Germany
19. April 2022
eGenesis Promotes Michael Curtis, Ph.D., to Chief Executive Officer
13. April 2022
ONWARD Announces Additions to Leadership Team
11. April 2022
PEI Regulatory Approval Received for Government Funded (€ 7.4 Million) Clinical Trial Investigating Adrenomed’s Adrecizumab in Treating Endothelial Barrier Dysfunction in Hospitalized COVID-19 Patients
7. April 2022
ONWARD Medical’s Parkinson’s Therapy Published in New England Journal of Medicine
4. April 2022
eGenesis Appoints Eliezer Katz, M.D., FACS, as Chief Medical Officer
28. March 2022
ONWARD adds new brain-spine interface and Parkinson’s disease IP to license agreements
15. March 2022
Adrenomed Supervisory Board appoints Dr. Richard Jones as CEO
9. March 2022
First participants enrolled in ONWARD’s LIFT home study
7. February 2022
ONWARD medical’s technology enables walking and standing after severe spinal cord injuries
12. January 2022
Moderna and Carisma establish collaboration to develop in vivo engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
10. January 2022
Creative Balloons appoints David Johnson as Chairman of the Board of Directors
16. December 2021
ONWARD Announces Completion of Enrollment in the Up- LIFT Pivotal Trial of ARC Therapy for Spinal Cord Injury
14. December 2021
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
7. December 2021
ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Gamma-delta T Cells in Science Translational Medicine
7. December 2021
Confo Therapeutics Enters Collaborative Agreement With Regeneron
6. October 2021
iOmx Therapeutics raises EUR 65 million in Series B round
17. September 2021
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
26. August 2021
TRiCares Announces Successful First in Human Implantations of Minimally Invasive Topaz Tricuspid Heart ...
23. June 2021
Quanta Raises $245 Million to Accelerate Commercialization of its SC+ Portable Hemodialysis System
9. April 2021
Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response
6. April 2021
UroMems Completes €23 Million Series B Financing
18. March 2021
Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs
4. March 2021
Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications
2. March 2021
eGenesis Announces $125 Million Series C Financing
24. February 2021
Creative Balloons closes €15 million growth financing and appoints Frank Gehres as CEO
29. January 2021
ONWARD Announces Publication in Nature Demonstrating Blood Pressure Stabilization in People with Spinal Cord Injury
12. January 2021
ONWARD Announces First Patient Enrolled in the Up-LIFT Pivotal Trial Assessing Safety and Effectiveness of ARC Therapy for Spinal Cord Injury
12. January 2021
ONWARD Completes $32 Million Financing Round
8. January 2021
Quanta Receives FDA 510(k) Clearance for the SC+ Hemodialysis System Setting the Stage for US Market Launch
8. January 2021
PerkinElmer to Acquire Oxford Immunotec Global PLC
8. January 2021
CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies
8. January 2021
CARISMA Therapeutics Appoints Richard Morris as Chief Financial Officer
15. December 2020
MinervaX raises upsized EUR 47.4M (USD 57M) Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials
15. December 2020
Adrenomed Supervisory Board appoints Dr. Wolfgang Baiker as CEO
11. November 2020
Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference
5. November 2020
Koa Health secures over €14m initial funding and spins out of Telefónica’s moonshot factory
28. October 2020
Digital therapeutics leader Sidekick raises $20M in Series A funding round led by Wellington and Asabys
27. July 2020
CARISMA Therapeutics announces FDA clearance of IND application for first-ever engineered macrophage immunotherapy
2. July 2020
Immatics announces completion of business combination and listing on NASDAQ
Confo Therapeutics expands board with appointment of Rob Scott as Independent Director
9. June 2020
GTX Medical was granted FDA Breakthrough Device Designation for Go-2 Targeted Epidural Spinal Stimulation (TESS) system
4. June 2020
Confo Therapeutics appoints Paolo Vicini as Chief Development Officer
26. May 2020
Wellington Partners’s portfolio company Themis to be acquired by MSD
14. May 2020
Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 Vaccine Candidate in France
27. April 2020
UroMems appoints medical device industry leader Steffen Hovard to Board of Directors
20. April 2020
GTX Medical appoints John Murphy as Chief Technology Officer
17. April 2020
Themis announces Iain Dukes to join the company’s supervisory board
16. April 2020
STipe Therapeutics appoints Dr Natalie Sacks as Independent Board Member and Dr Richard Bethell as Chief Development Officer
15. April 2020
Wellington invests in SIRS Therapeutics to develop FX06 for treatment of ARDS in COVID-19 patients in collaboration with F4 Pharma
26. March 2020
First patient dosed in EVICTION trial evaluating ImCheck’s lead anti-cancer drug ICT01
24. March 2020
Carisma Therapeutics: First-of-its-kind engineered macrophage cell therapy platform shows ability to reduce tumor burden & activate anti-tumor immunity, improving overall survival in pre-clinical cancer models
8. January 2020
Karl Naegler joins Wellington Partners as Managing Partner
4. December 2019
Wellington Partners participates in $53 Million Series B financing at ImCheck
7. November 2019
Wellington Partners participates in $100 Million Series B financing at eGenesis
25. October 2019
UroMems wins prestigious Prix Galien Med’Start-Up for best collaboration in the medtech or digital sector
22. October 2019
GTX medical & NeuroRecovery Technologies merge to create leading neurostimulation company for SCI
1. October 2019
Themis and ZIKAVAX consortium announce initiation of Phase 1 Zika vaccine trial
30. September 2019
STipe Therapeutics launches with EUR 20 million Series A financing
30. September 2019
iOmx Therapeutics announces discovery of novel, druggable immune-checkpoint targets
30. September 2019
AMBOSS raises €30M in Series B
26. September 2019
Adrenomed completes full enrollment with 300 patients in AdrenOSS-2 trial with Adrecizumab in septic shock
23. September 2019
FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019
18. September 2019
Themis raises EUR 40 Million in Series D financing round backed by US/EU consortium
29. August 2019
Adrenomed Supervisory Board appoints Jens Schneider-Mergener as CEO & Jens Zimmermann (CMO) joins the Executive Board
28. August 2019
Immatics and Celgene enter strategic collaboration to develop novel adoptive cell therapies
22. August 2019
Themis announces exclusive license and research collaboration agreement with MSD to develop vaccine candidates
31. July 2019
Wellington Partners raises EUR 210 million life science fund
29. July 2019
Quanta raises $48 million in Series C funding round
8. July 2019
Immatics appoints Harpreet Singh as Chief Executive Officer
21. June 2019
Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication
4. June 2019
CEPI awards up to US$21 million to Themis for Phase 3 Chikungunya Vaccine Development
28. May 2019
US patent grants strengthen SNIPR BIOME’s approach to enhance immuno-oncology outcomes by microbiome modulation
7. May 2019
Wellington Partners co-leads €30 million Series A financing in Confo Therapeutics
11. March 2019
SNIPR BIOME raises $50 million Series A financing to advance CRISPR-based microbiome drugs to human clinical trials
27. February 2019
Immatics announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers
27. February 2019
Themis receives FDA fast track designation for Chikungunya vaccine candidate
7. January 2019
AYOXXA signs research agreement in the field of ophthalmology with one of the leading pharmaceutical companies
26. November 2018
Adrenomed closes €24 million financing led by Wellington Partners and HBM
6. November 2018
Themis publishes compelling Phase 2 results for lead vaccine candidate against Chikungunya fever in "The Lancet"
11. October 2018
Themis announces exclusive licensing agreement with Max-Planck-Innovation to develop and commercialize oncolytic virotherapies
9. October 2018
Sphingotec raises €20 million from HBM and Wellington Partners
6. September 2018
Themis presents Phase II interim results for Chikungunya vaccine candidate at ASTMH 2017
27. June 2018
Carisma Therapeutics announces $53 million Series A financing
4. June 2018
TRiCares closes €22 million Series B financing round
27. March 2018
4SC: Yakult Honsha joins pivotal RESMAIN study of resminostat in CTCL
6. March 2018
CEPI partners with Themis to advance vaccines against Lassa fever and MERS
26. February 2018
Themis establishes Scientific Advisory Board of experts in virology and vaccine development
1. February 2018
Physicians at Helios gain access to Amboss platform
17. January 2018
Immatics appoints Thomas Ulmer as Chief Financial Officer
4. January 2018
Themis raises EUR 10 million in Series C financing to advance clinical pipeline
25. October 2017
Ambu acquires Wellington Partners portfolio company invendo medical
4. October 2017
Immatics receives $58 million in financing to develop T-cell receptor based immunotherapies
28. September 2017
Immatics initiates first Phase I clinical trial of ACTengine® approach in patients with advanced solid cancers
8. September 2017
Wellington featured in BioCentury
6. September 2017
MSD to acquire Rigontec
5. September 2017
Themis: Chikungunya vaccine development towards Phase III trials receives £ 3 Mio. boost by Innovate UK
21. August 2017
Immatics initiates personalized adoptive cellular therapy in patients with relapsed and/or refractory solid cancers using its pioneering target warehouse
27. July 2017
Themis starts Phase II clinical study of Chikungunya vaccine in endemic area
6. July 2017
4SC secures EUR 41 million from successful capital increase
8. June 2017
Themis starts Phase II trial of Chikungunya vaccine in the U.S.
3. May 2017
Rigontec starts FIH Phase I/II trial of RIG-I agonist RGT100 & appoints new CMO
7. December 2016
AYOXXA appoints permanent CEO
5. December 2016
invendo medical announces CE mark
17. November 2016
Chiesi Group acquires Atopix
15. November 2016
Wellington invests in Uromems
14. November 2016
Rigontec appoints new CSO
7. November 2016
Ayoxxa announces new CEO
7. November 2016
Immatics and Amgen sign $1B deal
5. October 2016
4SC: overall survival benefit for resminostat in first-line liver cancer study subgroup
